T
Tavotek Biotherapeutics
Biopharmaceutical innovations targeting cancer and debilitating diseases with advanced monoclonal antibodies and multi-specific biologics
About Tavotek Biotherapeutics
Tavotek Biotherapeutics is a biotech startup that operates in the field of cancer treatment. The company is primarily focused on the development of innovative therapies for solid tumors, a type of cancer that begins in the solid organs such as the lungs, colon, or breast. Tavotek's main product is TAVO412, a multispecific biologic, which is currently in the first phase of human clinical trials. A multispecific biologic is a type of drug that can target multiple parts of a cancer cell at once, potentially making it more effective at stopping the disease.
The company also offers a range of platforms that support the development of these treatments. TavoSELECT™ is a library of antibodies or biomolecules that can target different types of proteins, including those that are hard to reach because they are protected by the blood-brain barrier. TavoPRECISE™ is a platform for developing monoclonal antibodies and multispecific biologics, which are types of drugs that can target specific cells. TavoELITE™ is a novel platform that targets intracellular, or inside the cell, targets for the treatment of cancer and other diseases.
Tavotek Biotherapeutics serves a global market, with operations in both the United States and China. The company's business model is based on the research, development, and eventual commercialization of its cancer treatments. Its revenue will primarily come from the sales of these treatments once they have been approved for use.
In summary, Tavotek Biotherapeutics is a promising biotech startup that is developing innovative cancer treatments. Its multispecific biologics and targeted platforms could potentially revolutionize the way we treat solid tumors and other diseases.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $35M | $140M | CS Capital · Fontus Capital | ↗ |
| SERIES AOther financing | Mar 2021 | $20M | $80M | Oriza Holdings · New Alliance Capital · CTS Capital Advisors · Ming Bioventures | — |
Growth signals
Latest recorded traffic for Tavotek Biotherapeutics is 100 monthly website visits, down 95.5% over the last three months. Tavotek Biotherapeutics's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tavotek Biotherapeutics in the Lower Gwynedd Township ecosystem
The Tavotek Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Apricot Capital
Yuansheng BioVenture
Oriza Holdings
New Alliance Capital- CACTS Capital Advisors
Ming Bioventures- LCLanhu Capital
- GIGF Xinde Investment
- YCYuanBio Venture Capital
CS Capital- FCFontus Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tavotek Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tavotek Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





